Dual biological therapy and small molecules in pediatric inflammatory bowel disease
Inflammatory bowel diseases (IBDs) including Crohn’s disease (CD), ulcerative colitis (UC) and inflammatory bowel disease unclassified (IBD-U) are chronic inflammatory disorders which can affect the gastrointestinal tract. Anti-tumor necrosis factors antibodies (anti-TNFα) such as infliximab (IFX) a...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-10-01
|
| Series: | Pharmacological Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1043661823002918 |
| _version_ | 1827794291239419904 |
|---|---|
| author | Francesca Penagini Luisa Lonoce Luisa Abbattista Valentina Silvera Giulia Rendo Lucia Cococcioni Dario Dilillo Valeria Calcaterra Gian Vincenzo Zuccotti |
| author_facet | Francesca Penagini Luisa Lonoce Luisa Abbattista Valentina Silvera Giulia Rendo Lucia Cococcioni Dario Dilillo Valeria Calcaterra Gian Vincenzo Zuccotti |
| author_sort | Francesca Penagini |
| collection | DOAJ |
| description | Inflammatory bowel diseases (IBDs) including Crohn’s disease (CD), ulcerative colitis (UC) and inflammatory bowel disease unclassified (IBD-U) are chronic inflammatory disorders which can affect the gastrointestinal tract. Anti-tumor necrosis factors antibodies (anti-TNFα) such as infliximab (IFX) and adalimumab (ADA) are the first line biological therapy for severe or complicated IBDs in pediatric age. Second line therapeutic options as vedolizumab (VDZ) and ustekinumab (UST) are currently used off-label in pediatric age. Furthermore, despite optimization of biologics, a great proportion of patients may fail to respond to biologic agents (up to 30%) or lose response over the time (around 50%) hence these patients may be left without another valid therapeutic option. Consequently, several efforts have been made in the last years in order to develop new drugs and to contrive new therapeutic strategies. Small molecule drugs (SMDs) and combination therapy with either two biologic agents or with a SMD and a biological agent have recently been proposed. Data on safety and efficacy of these new therapeutic options are limited. The objective of the present review is to summarize the most up-to-date available literature in pediatric IBD. |
| first_indexed | 2024-03-11T18:31:35Z |
| format | Article |
| id | doaj.art-194b59ac6ff846169a3839df9fb9bbee |
| institution | Directory Open Access Journal |
| issn | 1096-1186 |
| language | English |
| last_indexed | 2024-03-11T18:31:35Z |
| publishDate | 2023-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Pharmacological Research |
| spelling | doaj.art-194b59ac6ff846169a3839df9fb9bbee2023-10-13T11:03:43ZengElsevierPharmacological Research1096-11862023-10-01196106935Dual biological therapy and small molecules in pediatric inflammatory bowel diseaseFrancesca Penagini0Luisa Lonoce1Luisa Abbattista2Valentina Silvera3Giulia Rendo4Lucia Cococcioni5Dario Dilillo6Valeria Calcaterra7Gian Vincenzo Zuccotti8Department of Pediatrics, ''Vittore Buzzi'' Children’s Hospital, Milano, Italy; Correspondence to: Department of Pediatrics, ''Vittore Buzzi'' Children’s Hospital, Via Castelvetro 32, 20154, Milano, Italy.Department of Pediatrics, ''Vittore Buzzi'' Children’s Hospital, Milano, ItalyDepartment of Pediatrics, ''Vittore Buzzi'' Children’s Hospital, Milano, ItalyDepartment of Pediatrics, ''Vittore Buzzi'' Children’s Hospital, Milano, ItalyDepartment of Pediatrics, ''Vittore Buzzi'' Children’s Hospital, Milano, ItalyDepartment of Pediatrics, ''Vittore Buzzi'' Children’s Hospital, Milano, ItalyDepartment of Pediatrics, ''Vittore Buzzi'' Children’s Hospital, Milano, ItalyDepartment of Pediatrics, ''Vittore Buzzi'' Children’s Hospital, Milano, Italy; Pediatric and Adolescent Unit, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, ItalyDepartment of Pediatrics, ''Vittore Buzzi'' Children’s Hospital, Milano, Italy; Department of Biomedical and Clinical Science “L. Sacco”, University of Milano, Milano, ItalyInflammatory bowel diseases (IBDs) including Crohn’s disease (CD), ulcerative colitis (UC) and inflammatory bowel disease unclassified (IBD-U) are chronic inflammatory disorders which can affect the gastrointestinal tract. Anti-tumor necrosis factors antibodies (anti-TNFα) such as infliximab (IFX) and adalimumab (ADA) are the first line biological therapy for severe or complicated IBDs in pediatric age. Second line therapeutic options as vedolizumab (VDZ) and ustekinumab (UST) are currently used off-label in pediatric age. Furthermore, despite optimization of biologics, a great proportion of patients may fail to respond to biologic agents (up to 30%) or lose response over the time (around 50%) hence these patients may be left without another valid therapeutic option. Consequently, several efforts have been made in the last years in order to develop new drugs and to contrive new therapeutic strategies. Small molecule drugs (SMDs) and combination therapy with either two biologic agents or with a SMD and a biological agent have recently been proposed. Data on safety and efficacy of these new therapeutic options are limited. The objective of the present review is to summarize the most up-to-date available literature in pediatric IBD.http://www.sciencedirect.com/science/article/pii/S1043661823002918Inflammatory Bowel DiseasePediatricDual biological TherapySmall molecules |
| spellingShingle | Francesca Penagini Luisa Lonoce Luisa Abbattista Valentina Silvera Giulia Rendo Lucia Cococcioni Dario Dilillo Valeria Calcaterra Gian Vincenzo Zuccotti Dual biological therapy and small molecules in pediatric inflammatory bowel disease Pharmacological Research Inflammatory Bowel Disease Pediatric Dual biological Therapy Small molecules |
| title | Dual biological therapy and small molecules in pediatric inflammatory bowel disease |
| title_full | Dual biological therapy and small molecules in pediatric inflammatory bowel disease |
| title_fullStr | Dual biological therapy and small molecules in pediatric inflammatory bowel disease |
| title_full_unstemmed | Dual biological therapy and small molecules in pediatric inflammatory bowel disease |
| title_short | Dual biological therapy and small molecules in pediatric inflammatory bowel disease |
| title_sort | dual biological therapy and small molecules in pediatric inflammatory bowel disease |
| topic | Inflammatory Bowel Disease Pediatric Dual biological Therapy Small molecules |
| url | http://www.sciencedirect.com/science/article/pii/S1043661823002918 |
| work_keys_str_mv | AT francescapenagini dualbiologicaltherapyandsmallmoleculesinpediatricinflammatoryboweldisease AT luisalonoce dualbiologicaltherapyandsmallmoleculesinpediatricinflammatoryboweldisease AT luisaabbattista dualbiologicaltherapyandsmallmoleculesinpediatricinflammatoryboweldisease AT valentinasilvera dualbiologicaltherapyandsmallmoleculesinpediatricinflammatoryboweldisease AT giuliarendo dualbiologicaltherapyandsmallmoleculesinpediatricinflammatoryboweldisease AT luciacococcioni dualbiologicaltherapyandsmallmoleculesinpediatricinflammatoryboweldisease AT dariodilillo dualbiologicaltherapyandsmallmoleculesinpediatricinflammatoryboweldisease AT valeriacalcaterra dualbiologicaltherapyandsmallmoleculesinpediatricinflammatoryboweldisease AT gianvincenzozuccotti dualbiologicaltherapyandsmallmoleculesinpediatricinflammatoryboweldisease |